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To the Editor,
Rimm et al. challenge our study demonstrating an associ-
ation between PD-L1 expression and poor prognosis in
human breast cancer [1] raising a concern about the anti-
body we used for immunohistochemistry.
Rimm et al. refer to ab58810 (Abcam) as an unvalidated
antibody. We share Rimm et al.’s concern about the use of
unvalidated antibodies in immunohistochemistry studies,
and we performed validation studies of the ab58810 anti-
body prior to using it in our study. Specifically, we
screened several anti-PD-L1 antibodies for tissue speci-
ficity using human term placenta and lymphoid tissue, as
mentioned in our paper [1]. Human term placenta is
commonly used for the validation of anti-PD-L1 antibodies
and was used by Rimm et al. for validation of anti-PD-L1
antibodies in their manuscript on PD-L1 expression in non-
small cell lung cancer (NSCLC) [2]. We tested several
antigen retrieval and staining protocols until we were sat-
isfied with the specificity of tissue staining. With an opti-
mized protocol using ab58810, we observed strong staining
of the trophoblast layer in human term placenta but the
absence of staining in the stromal cells and vessels of the
chorionic villi, as can be appreciated in Figs. 1–3. In ton-
sils, strong granular cytoplasmic staining of PD-L1 was
observed in follicular dendritic cells (Fig. 4). It is impor-
tant to recognize the fact that Rimm et al. report a lack of
tissue specificity with ab58810 in their study [2] does not
preclude the possibility that a positive result can be
obtained with a different staining protocol. The ab58810
antibody also recognizes the PD-L1 antigen in Western
blot analysis, as demonstrated on the Abcam website
(http://www.abcam.com/cd274-antibody-ab58810.html).
Rimm et al. also comment on nuclear staining observed
in some breast cancer cells in Fig. 1 of our manuscript [1].
Of note, the majority of breast cancer cells in Fig. 1 clearly
show cytoplasmic staining. We have attached additional
images from our breast cancer tissue micro array (TMA),
confirming that the staining was predominantly cytoplas-
mic (Figs. 5–7). We acknowledge that staining is observed
in some apoptotic nuclei, but this nuclear staining was not
considered for the evaluation of PD-L1 expression. As
stated in the Material & Methods section of our paper [1],
only cytoplasmic and membranous staining was considered
specific.
Of note, we have previously evaluated our TMA for the
presence of PD-1? tumor-infiltrating lymphocytes (TIL) [3].
We observed a statistically significant association between
PD-L1 expression by tumor cells and the presence of PD-1?
TIL in the same tumors (p \ 0.001). This observation pro-
vides additional evidence to support the integrity of immu-
nohistochemical staining in our manuscript.
In preparation of this response, we stained our breast
cancer TMA with an additional, newly developed anti-PD-
L1 antibody (clone E1L3 N, Cell Signaling), which has been
validated by Rimm et al. according to their recent ASCO
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poster (Domain-specific PD-L1 protein measurement in non-
small cell lung cancer; http://meetinglibrary.asco.org/con
tent/132010-144). With this clone, we observed a strong
association between PD-L1 expression and poor tumor dif-
ferentiation (G3), estrogen receptor (ER) negativity and
worse survival. These findings further support the notion that
PD-L1 protein expression is associated with poor prognosis
in breast cancer.
We acknowledge that our results are not consistent with
Schalper’s et al. findings that PD-L1 mRNA expression is
associated with better prognosis in breast cancer [4].
However, our study is consistent with the results of Ghebeh
et al. who reported an association in breast cancer between
PD-L1 expression and higher tumor grade, HER2 expres-
sion, absence of ER expression [5], and high Ki-67
expression [6], which are all known negative prognostic
factors. Furthermore, there are numerous reports in the
literature that expression of PD-L1 is associated with poor
prognosis in melanoma [7], NSCLC [8], renal cancer [9],
ovarian cancer [10], esophageal cancer [11], pancreatic
cancer [12], and gastric cancer [13]. Importantly, the study
about renal cancer was performed utilizing the PD-L1
clone M5H1, which Rimm et al. claim to be the only
validated antibody [2], and the study on esophageal cancer
was performed analyzing PD-L1 gene expression [11].
There are important differences between our study and
that of Schalper et al. [4] that may explain the disparate
results. First, our study evaluated PD-L1 protein expression
by immunohistochemistry, while Schalper et al. evaluated
PD-L1 mRNA expression. Although PD-L1 mRNA
expression appears to be associated with PD-L1 protein
expression, additional studies will need to be performed to
confirm this observation. Second, there is a significant
difference in the percentage of patients who are positive for
PD-L1 protein expression (23.1 % in our study) vs. PD-L1
mRNA expression (55.7, and 59.5 % in Schalper et al.).
The significantly different thresholds for considering
tumors positive for PD-L1 expression could substantially
Figs. 1–3 Human placental tissue stained with the anti-PD-L1
antibody clone ab58810, demonstrating intense staining of the
trophoblast layer and the absence of staining in the stromal and
vascular regions
Fig. 4 Human tonsil stained with the anti-PD-L1 antibody clone
ab58810, demonstrating strong granular cytoplasmic staining of the
follicular dendritic cells and the absence of staining in the surround-
ing lymphocytes
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affect the results observed. Third, there is a significant
difference in the cohorts studied. Our cohort appeared to
include patients with more aggressive disease as 72 % had
primary tumors that were pT2 and above (compared to
18 % in Schalper et al.), and 44 % had lymph node
metastases (compared to 19.6 % in Schalper et al.).
Although the lack of proliferation rate and other bio-
markers in the cohort of Schalper et al. precludes an
approximation of intrinsic subtype, it appears that this
cohort has a greater representation of smaller, ER-positive
and HER2-negative tumors (most probably Luminal type).
Of note, we observed that there was no association between
PD-L1 expression and survival in Luminal A breast cancers
(p = 0.132), while it was highly significant in the HER2-
(p = 0.013) and basal-like subtypes (p \ 0.001).
We agree that the absence of a validated standardized
staining and analysis protocol for PD-L1 has contributed to
concerns about the reliability of immunohistochemistry
staining for PD-L1. We were aware of this limitation when
we initiated our study and openly discussed this issue in
our paper [1]. We also acknowledge that we failed to
sufficiently explain the antibody validation in the Materials
& Methods section of our paper.
The role of PD-L1 expression in various human cancers
is still not completely understood, and conflicting results
have been reported. The impact of PD-L1 expression on
cancer biology may depend on the level of PD-L1
expression, tissue localization, and clinical context. It is
therefore clear that additional studies need to be performed
in order to validate preliminary results and define the
clinical significance. This is particularly important given
the promising results to date with novel therapeutics tar-
geting the PD-1/PD-L1 pathway.
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